The biology and treatment of EML4-ALK non-small cell lung cancer
Top Cited Papers
- 26 April 2010
- journal article
- research article
- Published by Elsevier in European Journal Of Cancer
- Vol. 46 (10) , 1773-1780
- https://doi.org/10.1016/j.ejca.2010.04.002
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- A Novel, Highly Sensitive Antibody Allows for the Routine Detection ofALK-Rearranged Lung Adenocarcinomas by Standard ImmunohistochemistryClinical Cancer Research, 2010
- The global burden of cancer: priorities for preventionCarcinogenesis: Integrative Cancer Research, 2009
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALKJournal of Clinical Oncology, 2009
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western PopulationClinical Cancer Research, 2009
- EML4-ALK Rearrangement in Non-Small Cell Lung Cancer and Non-Tumor Lung TissuesThe American Journal of Pathology, 2009
- A mouse model for EML4-ALK -positive lung cancerProceedings of the National Academy of Sciences, 2008
- EML4-ALKFusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung CancerClinical Cancer Research, 2008
- Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patientsBritish Journal of Cancer, 2008
- EML4–ALK fusion transcript is not found in gastrointestinal and breast cancersBritish Journal of Cancer, 2008